Groups Parameters  Total lipids(g/L) Triglycerides(mg/dl) Totalcholesterol(mg/dl) LDL-cholesterol(mg/dl) HDL-cholesterol(mg/dl) vLDL-cholesterol(mg/dl) LDL/HDL Total chol./HDL HMGCo-A/mevalonate
Normal 3.16±0.19c 42.75±1.37a 72.76±1.24b 29.90±0.63b 34.44±1.04a 8.55±0.27a 0.87±0.02b 2.11±0.05b 1.31±0.01b
Diabetic control 4.71±0.20a 46.07±2.38a 76.76±1.17a 37.49±2.79a 30.05±1.22a 9.21±0.07a 1.27±0.12a 2.56±0.06a 1.30±1.01b
Diabetic treatedwith 4b 4.03±0.08b 42.28±0.54a 67.89±0.90c 25.77±1.55b 33.67±2.33a 8.46±0.30a 1.31±0.06a 2.06±0.12b 1.59±2.10a
F-probability P<0.001 p>0.05 P<0.001 P<0.01 p>0.05 p>0.05 P<0.01 P<0.01 P<0.001
LSD at 5% level 0.49 - 3.36 5.65 - - 0.236 0.25 0.042
LSD at 1% level 0.68 - 4.65 7.82 - - 0.326 0.35 0.058
Table 8: Effect of pyrimido[1,6-a]quinazoline derivative 4b on serum lipid profile in n5-STZ induced type 2 diabetic male rats